NASDAQ: LQDALiquidia Corp Stock
$74.44+2.34 (+3.25%)
Updated Aug 14, 2026
LQDA Price
$74.44
Fair Value Price
N/A
Market Cap
$6.66B
52 Week Low
$21.15
52 Week High
$93.61
P/E
47.41x
P/B
34.15x
P/S
15.72x
PEG
0.74x
Dividend Yield
N/A
Revenue
$450.91M
Earnings
$138.61M
Gross Margin
92.5%
Operating Margin
39.06%
Profit Margin
30.7%
Debt to Equity
1.68
Operating Cash Flow
$168M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LQDA Overview
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LQDA's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
LQDA
Ranked#19 of 55
Ranked#19 of 55
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $58.86 | A | |
| $6.51 | A | |
| $39.01 | A |
Be the first to know about important LQDA news, forecast changes, insider trades & much more!
LQDA News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LQDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LQDA ($74.44) is trading above its intrinsic value of $40.48, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LQDA is poor value based on its earnings relative to its share price (47.41x), compared to the US market average (15.97x)
P/E vs Market Valuation
LQDA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more LQDA due diligence checks available for Premium users.
Valuation
LQDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
47.41x
Industry
3.6x
Market
15.97x
LQDA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LQDA is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
LQDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
34.15x
Industry
1.63x
LQDA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LQDA price to earnings growth (PEG)
For valuing profitable companies with growth potential
LQDA is good value based... subscribe to Premium to read more.
PEG Value Valuation
LQDA's financial health
Profit margin
Revenue
$171.7M
Net Income
$74.7M
Profit Margin
43.5%
LQDA's Earnings (EBIT) of $176.14M... subscribe to Premium to read more.
Interest Coverage Financials
LQDA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$521.9M
Liabilities
$326.8M
Debt to equity
1.68
LQDA's short-term assets ($437.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LQDA's short-term assets ($437.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LQDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LQDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$80.2M
Investing
-$12.2M
Financing
-$6.6M
LQDA's operating cash flow ($167.71M)... subscribe to Premium to read more.
Debt Coverage Financials
LQDA vs Pharmaceutical Stocks
Liquidia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.